Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
Read original at benzingaStocks · News reference
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Entera Bio financing lifts ENTX as investors weigh a $275 million cash boost, EB613 funding and dilution risk.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 4:03 PM
- Checked
- Jul 29, 2026, 4:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-08-18 AccNo: 0001178913-26-004178 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarEntera Bio Q2 EPS $(0.14) Misses $(0.08) Estimate
Read original at benzingaEntera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027
Read original at benzinga